
‼️ Lilly’s $4B Obesity Bet Just Got Cut in Half. Here’s What the Prescription Data Is Actually Telling Investors
Read More: https://bit.ly/FoundayoLosing
#ObesityDrugs #Biopharma #LillyStock #NovoNordisk #Foundayo #WegovyPill #PharmaceuticalInvesting #HealthcareInvesting #DrugPricing #Tirzepatide #Retatrutide #Semaglutide #PharmaWatch #EquityResearch #InvestorInsights #GLP1
